Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: "E Lang" Clear advanced filters

  • Important advances in Parkinson disease (PD) in 2015 included a revision of its clinical diagnostic criteria and a proposal for research criteria defining prodromal PD. Research published in the past year has also continued to expand our understanding of the roles of Lewy pathology and α-synuclein in the pathobiology of PD.

    • Lorraine V. Kalia
    • Anthony E. Lang
    News & Views
    Nature Reviews Neurology
    Volume: 12, P: 65-66

  • Drawing on data from social network studies, Dhand and colleagues suggest that focusing on a patient's personal network can help identify individuals at risk of poor health outcomes. The authors provide an overview of the terminology used in social network studies, discuss social network structures that put patients at risk, and suggest how social network research might be applied in the neurology clinic.

    • Amar Dhand
    • Douglas A. Luke
    • Jin-Moo Lee
    Reviews
    Nature Reviews Neurology
    Volume: 12, P: 605-612

  • Mutations in six genes have been unequivocally linked to Parkinson disease (PD). A recent study found that among 953 patients with the early-onset form of PD, ≈17% harbored a mutation in one of these genes. This finding raises important issues concerning genetic testing and genetic counseling for early-onset PD.

    • Christine Klein
    • Ana Djarmati
    News & Views
    Nature Reviews Neurology
    Volume: 7, P: 7-9

  • The discovery of mutations that contribute to movement disorders has facilitated the identification of converging pathways and novel therapeutic targets. Successful translation of these research findings into clinical practice will require identification of early markers of disease progression, and recent research indicates that progress is being made in this area.

    • Christine Klein
    • Dimitri Krainc
    News & Views
    Nature Reviews Neurology
    Volume: 8, P: 65-66

  • In this Perspectives article, Espay and colleagues argue that that the adoption of precision medicine in Parkinson disease will require a revision of biomarker development efforts, with the ultimate goal of testing putative disease-modifying interventions in well-defined disease subgroups.

    • Alberto J. Espay
    • Patrik Brundin
    • Anthony E. Lang
    Comments & Opinion
    Nature Reviews Neurology
    Volume: 13, P: 119-126